Genmab A/S (GMAB) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates strong financial performance with significant revenue and profit growth, a robust cash position, and high recurring revenue contribution. The share buyback program further reflects confidence in the company's future. The Q&A section highlights management's confidence in their product pipeline and strategic plans despite some lack of revenue guidance. Overall, the strong financial results and positive outlook on product development contribute to a positive sentiment, likely resulting in a stock price increase of 2% to 8%.
Key Financial Performance
Total Revenue Growth 19% year-over-year increase, driven by increased recurring revenue.
Operating Profit Growth 56% year-over-year increase, achieved despite strategic investments.
Cash Position Ended the first half with around $3 billion in cash, reinforcing financial strength and flexibility for growth.
EPKINLY Global Sales $211 million in the first half of 2025, a 74% year-over-year increase, driven by adoption across geographies and new patient starts.
Tivdak Global Sales $78 million in the first half of 2025, a 30% year-over-year increase, reflecting strong U.S. performance and new launches in Japan and Europe.
DARZALEX Net Sales $6.8 billion in the first half of 2025, a nearly 22% year-over-year increase, driven by share gains and strong performance in the frontline setting.
Recurring Revenue Contribution 97% of total revenue in the first half of 2025, compared to 90% in the first half of 2024, indicating improved revenue quality.
Total Operating Expenses (OpEx) Slightly less than $1 billion in the first half of 2025, a 6% year-over-year increase, excluding the impact of the ProFound Bio acquisition.
Net Profit $531 million in the first half of 2025, reflecting strong financial performance.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Epcoritamab (EPKINLY): Submitted an sBLA to the FDA for second-line follicular lymphoma in combination with rituximab and lenalidomide. FDA accepted the sBLA for priority review with a target action date of November 30, 2025. Phase III EPCORE FL-1 study met dual endpoints of progression-free survival and overall response rate, reducing disease progression or death risk by 79%. Expected peak sales exceeding $3 billion.
Rina-S: Phase I/II RAINFOL-01 study showed a 50% overall response rate in advanced endometrial cancer. Plans to initiate three Phase III trials in gynecologic cancers and a Phase II trial in non-small cell lung cancer. Expected peak sales exceeding $2 billion.
Acasunlimab: Launching a Phase II study for advanced melanoma and awaiting additional data for non-small cell lung cancer in the second half of the year.
EPKINLY and Tivdak: Global sales up 60% year-over-year, contributing 31% to total revenue growth. EPKINLY posted $211 million in global sales, a 74% year-over-year increase. Tivdak global sales totaled $78 million, up 30% year-over-year. Expanded into Japan and Europe.
Revenue Growth: Total revenue grew by 19%, driven by recurring revenues and product sales. Operating profit grew by 56%.
Financial Guidance: Improved 2025 revenue guidance to $3.5-$3.7 billion, with operating profit expected to grow 26% year-over-year.
Capital Allocation: Focused on high-impact late-stage pipeline programs and commercialization capabilities. Completed share buyback, ending the first half with $3 billion in cash.
Pipeline Expansion: Actively pursuing organic and inorganic growth opportunities to strengthen the pipeline.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory hurdles: The company faces potential challenges in obtaining global regulatory approvals for its products, such as Epcoritamab and Rina-S, despite positive clinical data. Regulatory delays or rejections could impact the timeline for commercialization and revenue generation.
Supply chain disruptions: Although not explicitly mentioned, the global geopolitical situation could pose risks to the supply chain, potentially affecting the production and distribution of key products like EPKINLY and Tivdak.
Market competition: The company operates in highly competitive markets for oncology treatments, which could impact the adoption and market share of its products like EPKINLY and Tivdak.
Economic uncertainties: Economic conditions, including currency fluctuations (e.g., dollar to kroner exchange rate), could impact financial performance, as noted in the discussion of FX sensitivity.
Strategic execution risks: The company is heavily investing in late-stage pipeline programs and commercialization efforts. Any failure in execution, such as delays in clinical trials or ineffective market launches, could adversely affect financial and operational performance.
Product safety and efficacy: While clinical trials have shown promising results, any unforeseen safety issues or lack of efficacy in broader patient populations could hinder product adoption and regulatory approvals.
Geopolitical risks: The company is monitoring geopolitical situations, which could potentially impact its business operations and financial guidance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: Genmab has increased its 2025 revenue guidance to a range of $3.5 billion to $3.7 billion, reflecting a 15% growth at the midpoint, up from the previous 12% growth guidance. This is driven by strong performance of DARZALEX and positive sales momentum for EPKINLY.
Recurring Revenue Growth: Recurring revenues for 2025 are now expected to grow by 22%, up from the previous guidance of 18%.
Operating Profit Guidance: Operating profit is projected to be in the range of $1.1 billion to $1.4 billion, with a midpoint of over $1.2 billion, representing a 26% year-over-year growth.
Product Sales Projections: EPKINLY is expected to achieve peak sales exceeding $3 billion by the end of the decade. Rina-S is projected to achieve peak sales exceeding $2 billion in ovarian and endometrial cancers.
Pipeline Development: Three Phase III trials for Rina-S are planned to be underway by the end of 2025, targeting platinum-resistant ovarian cancer, endometrial cancer, and platinum-sensitive ovarian cancer. A Phase II trial for Rina-S in non-small cell lung cancer is also planned to start in Q4 2025. A Phase II study for acasunlimab in advanced melanoma is being launched, with additional data expected in non-small cell lung cancer in the second half of 2025.
Regulatory Submissions and Approvals: The FDA has accepted the sBLA for epcoritamab in second-line follicular lymphoma for priority review, with a target action date of November 30, 2025. Global regulatory submissions for epcoritamab are planned based on positive Phase III trial results.
Commercial Expansion: EPKINLY and Tivdak are expected to drive long-term growth, with EPKINLY positioned as the core therapy across B-cell lymphomas. Tivdak is expanding into new markets, including Japan and Europe, with launches planned in Germany and other countries.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Program: No specific mention of a dividend program was made in the transcript.
Share Buyback Program: In June, the company completed a share buyback program. This action was highlighted as a demonstration of confidence in Genmab's future and a commitment to delivering value to shareholders.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the latest thinking on the positioning of epco versus other CD20 bispecifics in the competitive landscape?
A:Management expressed confidence in their broad and aggressive development plan for EPKINLY, highlighting their head start in second-line follicular lymphoma and the fully accrued frontline diffuse large B-cell study. They emphasized their leading sales position globally and the unique off-the-shelf dual indication bispecific nature of EPKINLY. They also mentioned submitting close to 30 abstracts on epcoritamab for ASH.
Q:How confident is the company in filing RAINFOL-01 Part C for accelerated approval and in avoiding FDA pushback on EPCORE FL-1?
A:Management stated confidence in filing RAINFOL-01 Part C for accelerated approval, provided the data supports it. They also expressed confidence in the EPCORE FL-1 pathway, noting active and positive engagement with the FDA and a PDUFA date in November.
Q:What is the initial launch strategy for EPKINLY assuming approval in November, and what are the revenue expectations for 2025 and 2026?
A:The initial launch strategy focuses on expanding into the community and targeting earlier lines of therapy, particularly second-line follicular lymphoma. Management did not provide specific revenue expectations for 2025 and 2026.
Q:Why was the HexaBody-OX40 program discontinued, and what is the confidence level in the HexaBody platform?
A:The HexaBody-OX40 program was discontinued due to its lack of differentiation and less promising development path compared to other opportunities. Management remains confident in the HexaBody platform and plans to bring a new program into the clinic by the end of the year.
Q:How does EPKINLY differentiate from mosunetuzumab in follicular lymphoma?
A:EPKINLY has a positive Phase III in second-line follicular lymphoma, providing a significant head start. It has shown better efficacy, higher CR rates, and advantages in subcutaneous administration and safety optimization compared to mosunetuzumab.
Q:What are the plans for Rina-S development outside ovarian cancer, particularly in non-small cell lung cancer?
A:Management plans to explore Rina-S in EGFR-mutated non-small cell lung cancer due to its folate receptor alpha expression. They have a small cohort generating safety data and plan to use a dedicated study with multiple arms to explore this and other solid tumor indications.
Q:What is the company's view on ADC combinations with epcoritamab?
A:Management sees ADC combinations as a promising area and plans to explore them further. They highlighted epcoritamab's combinability with various agents and its potential to become a backbone for novel combinations in the future.
Q:Will acasunlimab in melanoma use the same Q6-week dosing?
A:Yes, acasunlimab will use the same Q6-week dosing, as it has shown optimal efficacy and safety.
Q:What are the details of the Phase II trial for Rina-S in non-small cell lung cancer?
A:The Phase II trial will explore Rina-S in both monotherapy and combination settings. Management did not disclose specific details about the combinations or lines of therapy due to competitive considerations.
Q:Review of Unclear Management Responses
A:Management avoided providing specific revenue expectations for EPKINLY in 2025 and 2026, and they did not disclose detailed plans for the Phase II trial of Rina-S in non-small cell lung cancer, citing competitive reasons.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ASCO
DLBCL FL
EHA
EPKINLY development
EPKINLY patient
Executive VP
GJ
II study
LLC Research
Phase II
Phase III
Research Division
Rina milligram
Tivdak
analysis
cancer Phase
community
country
development program
endpoint
expansion
level
meter square
milligram meter
option
patient cancer
phase commercialization
receptor alpha
reimbursement
response rate
sBLA
term value
treatment paradigm
value creation
woman
GMAB Transcript
Genmab A/S (GMAB) Q1 2026 Earnings Call Transcript
Positive5-14
The earnings call highlights strong revenue growth projections, multiple product launches, and strategic market expansions, which are positive indicators. Although increased expenses for development and some ambiguity in trial details were noted, the overall sentiment remains positive due to optimistic guidance and strategic investments. The Q&A session did not reveal significant concerns that would alter this sentiment.
Genmab A/S (GMAB) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-11
Genmab A/S (GMAB) Q4 2025 Earnings Call Transcript
Positive2-17
The earnings call highlights strong future revenue projections, significant product pipeline developments, and strategic market expansions, which are positive indicators. The Q&A section reveals management's optimism about trial outcomes and market strategies, despite some vagueness in responses. The company's focus on strategic acquisitions and disciplined financial management further supports a positive outlook. However, the lack of interim trial details could cause some uncertainty. Overall, the strong revenue and product potential, combined with strategic growth plans, suggest a positive stock price movement in the short term.
Genmab A/S (GMAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
GMAB Slides
GMAB Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
